Cancer Genetics (CGIX) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Janney Capital Downgrades Cancer Genetics, Inc. (CGIX) to Neutral
March 11, 2016 7:09 AM ESTJanney Capital downgraded Cancer Genetics, Inc. (NASDAQ: CGIX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Cancer Genetics, Inc. click here. For more ratings news on Cancer Genetics, Inc. click here.
Shares of Cancer Genetics, Inc. closed at $2.67 yesterday.
... More